Cargando…
Enzyme Therapy: Current Challenges and Future Perspectives
In recent years, enzymes have risen as promising therapeutic tools for different pathologies, from metabolic deficiencies, such as fibrosis conditions, ocular pathologies or joint problems, to cancer or cardiovascular diseases. Treatments based on the catalytic activity of enzymes are able to conver...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8431097/ https://www.ncbi.nlm.nih.gov/pubmed/34502086 http://dx.doi.org/10.3390/ijms22179181 |
_version_ | 1783750857023553536 |
---|---|
author | de la Fuente, Miguel Lombardero, Laura Gómez-González, Alfonso Solari, Cristina Angulo-Barturen, Iñigo Acera, Arantxa Vecino, Elena Astigarraga, Egoitz Barreda-Gómez, Gabriel |
author_facet | de la Fuente, Miguel Lombardero, Laura Gómez-González, Alfonso Solari, Cristina Angulo-Barturen, Iñigo Acera, Arantxa Vecino, Elena Astigarraga, Egoitz Barreda-Gómez, Gabriel |
author_sort | de la Fuente, Miguel |
collection | PubMed |
description | In recent years, enzymes have risen as promising therapeutic tools for different pathologies, from metabolic deficiencies, such as fibrosis conditions, ocular pathologies or joint problems, to cancer or cardiovascular diseases. Treatments based on the catalytic activity of enzymes are able to convert a wide range of target molecules to restore the correct physiological metabolism. These treatments present several advantages compared to established therapeutic approaches thanks to their affinity and specificity properties. However, enzymes present some challenges, such as short in vivo half-life, lack of targeted action and, in particular, patient immune system reaction against the enzyme. For this reason, it is important to monitor serum immune response during treatment. This can be achieved by conventional techniques (ELISA) but also by new promising tools such as microarrays. These assays have gained popularity due to their high-throughput analysis capacity, their simplicity, and their potential to monitor the immune response of patients during enzyme therapies. In this growing field, research is still ongoing to solve current health problems such as COVID-19. Currently, promising therapeutic alternatives using the angiotensin-converting enzyme 2 (ACE2) are being studied to treat COVID-19. |
format | Online Article Text |
id | pubmed-8431097 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84310972021-09-11 Enzyme Therapy: Current Challenges and Future Perspectives de la Fuente, Miguel Lombardero, Laura Gómez-González, Alfonso Solari, Cristina Angulo-Barturen, Iñigo Acera, Arantxa Vecino, Elena Astigarraga, Egoitz Barreda-Gómez, Gabriel Int J Mol Sci Review In recent years, enzymes have risen as promising therapeutic tools for different pathologies, from metabolic deficiencies, such as fibrosis conditions, ocular pathologies or joint problems, to cancer or cardiovascular diseases. Treatments based on the catalytic activity of enzymes are able to convert a wide range of target molecules to restore the correct physiological metabolism. These treatments present several advantages compared to established therapeutic approaches thanks to their affinity and specificity properties. However, enzymes present some challenges, such as short in vivo half-life, lack of targeted action and, in particular, patient immune system reaction against the enzyme. For this reason, it is important to monitor serum immune response during treatment. This can be achieved by conventional techniques (ELISA) but also by new promising tools such as microarrays. These assays have gained popularity due to their high-throughput analysis capacity, their simplicity, and their potential to monitor the immune response of patients during enzyme therapies. In this growing field, research is still ongoing to solve current health problems such as COVID-19. Currently, promising therapeutic alternatives using the angiotensin-converting enzyme 2 (ACE2) are being studied to treat COVID-19. MDPI 2021-08-25 /pmc/articles/PMC8431097/ /pubmed/34502086 http://dx.doi.org/10.3390/ijms22179181 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review de la Fuente, Miguel Lombardero, Laura Gómez-González, Alfonso Solari, Cristina Angulo-Barturen, Iñigo Acera, Arantxa Vecino, Elena Astigarraga, Egoitz Barreda-Gómez, Gabriel Enzyme Therapy: Current Challenges and Future Perspectives |
title | Enzyme Therapy: Current Challenges and Future Perspectives |
title_full | Enzyme Therapy: Current Challenges and Future Perspectives |
title_fullStr | Enzyme Therapy: Current Challenges and Future Perspectives |
title_full_unstemmed | Enzyme Therapy: Current Challenges and Future Perspectives |
title_short | Enzyme Therapy: Current Challenges and Future Perspectives |
title_sort | enzyme therapy: current challenges and future perspectives |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8431097/ https://www.ncbi.nlm.nih.gov/pubmed/34502086 http://dx.doi.org/10.3390/ijms22179181 |
work_keys_str_mv | AT delafuentemiguel enzymetherapycurrentchallengesandfutureperspectives AT lombarderolaura enzymetherapycurrentchallengesandfutureperspectives AT gomezgonzalezalfonso enzymetherapycurrentchallengesandfutureperspectives AT solaricristina enzymetherapycurrentchallengesandfutureperspectives AT angulobartureninigo enzymetherapycurrentchallengesandfutureperspectives AT aceraarantxa enzymetherapycurrentchallengesandfutureperspectives AT vecinoelena enzymetherapycurrentchallengesandfutureperspectives AT astigarragaegoitz enzymetherapycurrentchallengesandfutureperspectives AT barredagomezgabriel enzymetherapycurrentchallengesandfutureperspectives |